^
Association details:
| Biomarker: | CXCL10 elevation |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Kimmtrak (tebentafusp-tebn) (CD3 agonist, gp100 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated anti-tumor immune responses in patients with metastatic melanoma
Published date:
08/17/2020
Excerpt:
84 patients with advanced melanoma received tebentafusp….Tebentafusp was generally well tolerated and active in both metastatic uveal melanoma (mUM) and metastatic cutaneous melanoma (mCM) patients….increased serum CXCL10 or the appearance of rash, (likely due to cytotoxic T cells targeting of gp100-expressing skin melanocytes) showed a positive association with patient survival.
DOI:
10.1158/1078-0432.CCR-20-1247
